Marc Armengol
Overview
Explore the profile of Marc Armengol including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
79
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ribeiro M, Profitos-Peleja N, Santos J, Blecua P, Reyes-Garau D, Armengol M, et al.
Front Immunol
. 2023 May;
14:1130052.
PMID: 37153563
Background: Immunotherapy-based regimens have considerably improved the survival rate of B-cell non-Hodgkin lymphoma (B-NHL) patients in the last decades; however, most disease subtypes remain almost incurable. TG-1801, a bispecific antibody...
2.
Sabatier M, Birsen R, Lauture L, Mouche S, Angelino P, Dehairs J, et al.
Cancer Discov
. 2023 Apr;
13(7):1720-1747.
PMID: 37012202
Significance: FLT3 mutations are found in 30% of AML cases and are actionable by tyrosine kinase inhibitors. Here, we discovered that C/EBPα regulates FA biosynthesis and protection from lipid redox...
3.
Dlouhy I, Armengol M, Recasens-Zorzo C, Ribeiro M, Perez-Galan P, Bosch F, et al.
Haematologica
. 2022 Dec;
107(12):2990.
PMID: 36453521
No abstract available.
4.
Montagut A, Armengol M, de Pablo G, Estrada-Tejedor R, Borrell J, Roue G
Semin Cell Dev Biol
. 2022 Feb;
132:213-229.
PMID: 35184940
As a post-translational modification that has pivotal roles in protein degradation, ubiquitination ensures that intracellular proteins act in a precise spatial and temporal manner to regulate diversified cellular processes. Perturbation...
5.
Ribeiro M, Reyes-Garau D, Vinyoles M, Profitos Peleja N, Santos J, Armengol M, et al.
Clin Cancer Res
. 2021 Sep;
27(23):6591-6601.
PMID: 34551904
Purpose: Despite the remarkable activity of BTK inhibitors (BTKi) in relapsed B-cell non-Hodgkin lymphoma (B-NHL), no clinically-relevant biomarker has been associated to these agents so far. The relevance of phosphoproteomic...
6.
Dlouhy I, Armengol M, Recasens-Zorzo C, Ribeiro M, Perez-Galan P, Bosch F, et al.
Haematologica
. 2021 May;
106(10):2749-2753.
PMID: 33979991
No abstract available.
7.
Mlakar V, Curtis P, Armengol M, Ythier V, Dupanloup I, Ben Hassine K, et al.
Sci Rep
. 2021 Mar;
11(1):5038.
PMID: 33658540
GSTA1 encodes a member of a family of enzymes that function to add glutathione to target electrophilic compounds, including carcinogens, therapeutic drugs, environmental toxins, and products of oxidative stress. GSTA1...
8.
Armengol M, Santos J, Fernandez-Serrano M, Profitos-Peleja N, Ribeiro M, Roue G
Cancers (Basel)
. 2021 Jan;
13(2).
PMID: 33430146
For years, immunotherapy has been considered a viable and attractive treatment option for patients with cancer. Among the immunotherapy arsenal, the targeting of intratumoral immune cells by immune-checkpoint inhibitory agents...
9.
Ribeiro M, Reyes-Garau D, Armengol M, Fernandez-Serrano M, Roue G
Front Genet
. 2019 Nov;
10:986.
PMID: 31681423
In the last 10 years, major advances have been made in the diagnosis and development of selective therapies for several blood cancers, including B-cell non-Hodgkin lymphoma (B-NHL), a heterogeneous group...